Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $793000.0.

  • Apellis Pharmaceuticals' Cash from Financing Activities fell 6880.41% to $793000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 9757.25%. This contributed to the annual value of $149.2 million for FY2024, which is 6216.95% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $793000.0 for Q3 2025, which was down 6880.41% from $6.6 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $391.1 million during Q1 2023, with a 5-year trough of -$15.9 million in Q4 2022.
  • For the 5-year period, Apellis Pharmaceuticals' Cash from Financing Activities averaged around $68.9 million, with its median value being $2.5 million (2024).
  • The largest annual percentage gain for Apellis Pharmaceuticals' Cash from Financing Activities in the last 5 years was 2298235.29% (2022), contrasted with its biggest fall of 20461.78% (2022).
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Cash from Financing Activities stood at $384.0 million in 2021, then crashed by 104.15% to -$15.9 million in 2022, then soared by 75.46% to -$3.9 million in 2023, then decreased by 2.22% to -$4.0 million in 2024, then skyrocketed by 119.82% to $793000.0 in 2025.
  • Its Cash from Financing Activities stands at $793000.0 for Q3 2025, versus $6.6 million for Q2 2025 and $274000.0 for Q1 2025.